NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Integer Holdings Corporation ("Integer Holdings Corporation" or the "Company") (NYSE: ITGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integer Holdings Corporation investors who were adversely affected by alleged securities fraud between July 25, 2024 and October 22, 2025. Follow the link below to get more information and be contacted by a member of our team: ...

Financial Data and Key Metrics Changes - Net sales for Q2 were $341 million, a 5% decline compared to Q2 last year [6][12] - Gross margin rate improved to 8.2%, a 160 basis point increase from 6.6% in the same period last year [12] - Adjusted operating income was $15.3 million, or 4.5% of net sales, compared to $13.3 million, or 3.7% of net sales last year [13] - Adjusted net income was $6.9 million, or $0.28 per diluted share, compared to $7.4 million, or $0.29 per diluted share last year [15] Business Line Data and Key Metrics Changes - Medical sales were $96 million, up 15% year-over-year, representing 28% of total company sales [6][8] - Automotive sales totaled $162 million, down 13% year-over-year, accounting for 48% of total sales [9] - Industrial sales were $83 million, a 5% decrease compared to Q2 last year, representing 24% of total sales [11] Market Data and Key Metrics Changes - Medical vertical growth was driven by increases in Poland and Thailand, while North America remained flat [7][8] - Automotive sales decline was primarily due to lower sales in North America and China, with some offset from growth in Poland and Romania [9][10] - Industrial business decline was concentrated in North America, with some recovery in Europe [11] Company Strategy and Development Direction - The company is focusing on the medical vertical as a key growth area, leveraging its capabilities in a highly regulated industry [5][8] - A rebranding to Kimball Solutions reflects the company's evolution beyond traditional manufacturing services, expanding into design, engineering, and supply chain management [20] - The grand opening of a new medical manufacturing facility in Indianapolis is part of the strategy to enhance capabilities and capacity [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the medical vertical's growth potential, driven by megatrends such as an aging population and increasing healthcare access [8] - The company raised its guidance for fiscal 2026, expecting net sales between $1.4 billion and $1.46 billion, driven by strength in the medical vertical and automotive programs [17][18] - Management is monitoring the outlook for FY27, particularly in North America automotive and industrial sectors, due to economic concerns and tariff impacts [19] Other Important Information - Cash and cash equivalents at the end of Q2 were $77.9 million, with cash generated from operations at $6.9 million [15][16] - The company invested $4.3 million in share repurchases during Q2, with a total of $109.5 million returned to shareholders since October 2015 [17] - The effective tax rate for Q2 was 47.9%, significantly higher than the previous year due to adjustments related to the sale of the Tampa facility [15] Q&A Session Summary Question: What percentage was Nexteer in December? - Nexteer accounted for 20% of sales in December [25][26] Question: What is the capacity and ramp expectations for the new facility in Indianapolis? - The new facility is 300,000 sq ft, significantly larger than the current footprint, with substantial growth opportunities [28] Question: How should we think about growth in the automotive piece for Q3 and Q4? - Q3 automotive is expected to be flat to slightly up as the company anniversaries the end of the EB100 program [37] Question: What are the win rates and sizes of new programs? - Win rates remain consistent, with larger programs expected from lift and shift opportunities and CMO discussions [39][40] Question: How will the new facility impact margins? - The new facility is expected to drag margins in the near term due to depreciation and additional expenses, but long-term margins are expected to improve [44][45] Question: How do you see cash cycle days play out in the coming quarters? - Cash conversion days are expected to decrease in Q3 from elevated levels in Q2 [49] Question: What are the opportunities in the medical space for acquisitions? - The company is interested in in vitro diagnostics and cardiology as potential areas for expansion [58]

NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Integer Holdings Corporation ("Integer Holdings Corporation" or the "Company") (NYSE: ITGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integer Holdings Corporation investors who were adversely affected by alleged securities fraud between July 25, 2024 and October 22, 2025. Follow the link below to get more information and be contacted by a member of our team: http ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as growth drivers, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline on February 9, 2026 [1] Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the Court by February 9, 2026 [3] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its performance in securities class actions [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5] - It is claimed that Integer overstated its visibility into customer demand and mischaracterized its EP devices as long-term growth drivers, leading to investor damages when the truth was revealed [5]

Core Insights - Kimball Electronics, Inc. (KE) is set to report its second-quarter fiscal 2026 results on February 4, with sales expected to decline by 4.2% year-over-year to $342.5 million and earnings estimated at 28 cents per share, reflecting a 3.5% decrease from the previous year [1][9]. Group 1: Earnings Performance - Kimball Electronics has consistently surpassed the Zacks Consensus Estimate in the last four quarters, with an average surprise of 49.71% [2]. - The current Earnings ESP for Kimball Electronics is 0.00%, and it holds a Zacks Rank of 3 (Hold), indicating uncertainty regarding an earnings beat this time [7]. Group 2: Factors Influencing Q2 Results - The company's second-quarter results are expected to benefit from its expansion in the high-growth medical contract manufacturing sector, particularly with a new 300,000 sq. ft. facility in Indianapolis [3]. - Demand for medical devices is driven by an aging population, increased healthcare access, and advancements in connected drug-delivery systems, which are anticipated to positively impact Kimball Electronics' performance [4]. - Operational improvements, including reduced inventory and lower selling, general, and administrative expenses, along with significant debt reduction, are likely to enhance the bottom line for the quarter [5]. Group 3: Industry Challenges - Despite the positive factors, overall results may be negatively impacted by industry-wide softness in the automotive and industrial segments, which could outweigh the strong performance in the medical division [6]. - The company's heavy reliance on a few large medical and automotive customers presents an additional concern [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements, including over $438 million for investors in 2019, and has been recognized as a leader in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and the performance of its EP devices [5]. - It is claimed that Integer misrepresented its sales and growth prospects, leading to investor damages when the true situation was revealed [5].

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Integer Holdings Corporation (NYSE: ITGR). Shareholders who purchased shares of ITGR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/integer-holdings-corporation-loss-submission-form/?id=183275&from=4  CLASS ...

NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Integer Holdings Corporation (NYSE: ITGR). Shareholders who purchased shares of ITGR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/integer-holdings-corporation-loss-submission-form/?id=183250&from=3 CLA ...

Core Insights - Confluent Medical Technologies has launched Filmcast Select™, a materials customization program for polymer tubing that allows customers to select key performance attributes of Filmcast PTFE and polyimide tubing [1][2] Group 1: Product Offering - The standard Filmcast polymer tubing process lacks customization, which is increasingly necessary as medical devices become smaller and more complex; Filmcast Select™ addresses this need by allowing OEMs to choose tubing based on critical characteristics such as flexibility, strength, durability, surface finish, regulatory compliance, and optical clarity [2][3] - Filmcast Select™ includes multiple polyimide tubing options, such as standard polyimide, REACH-compliant glossy and matte polyimide, and Ultra Polyimide, offering benefits like high transparency, reduced friction, and nearly double the tensile strength of standard polyimide for thin-wall designs [3][4] - The program also features various Filmcast PTFE options, including FlexaCast™ for increased flexibility, DuraCast™ for enhanced abrasion resistance, and UltraCast™ for higher tensile strength in demanding applications [4] Group 2: Customer Collaboration - Confluent Medical can collaborate with customers on preferred PTFE dispersions, enabling OEMs to utilize existing biocompatibility data and shorten development time for new or next-generation devices [4] Group 3: Company Background - Confluent Medical specializes in the design, development, and large-scale manufacturing of interventional catheter-based devices and implants, with expertise in Nitinol materials, balloon and complex catheters, high-precision polymer tubing, and implantable textiles [5] - The company operates facilities in multiple locations, including California, Rhode Island, Maine, Texas, Tennessee, Costa Rica, and India, and has established a strong reputation in the medical device community through innovative materials science and engineering [5]